H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on PDS Biotechnology (PDSB – Research Report) today and set a price target of $15.00. The company's shares closed last Friday at $7.42. According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.7% and a 27.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. PDS Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $18.50. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $17.
https://www.tipranks.com/news/blurbs/pds-biotechnology-pdsb-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral